ATE460479T1 - Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon - Google Patents

Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon

Info

Publication number
ATE460479T1
ATE460479T1 AT03798512T AT03798512T ATE460479T1 AT E460479 T1 ATE460479 T1 AT E460479T1 AT 03798512 T AT03798512 T AT 03798512T AT 03798512 T AT03798512 T AT 03798512T AT E460479 T1 ATE460479 T1 AT E460479T1
Authority
AT
Austria
Prior art keywords
adamts
antibody
cliping
antibodies
assay system
Prior art date
Application number
AT03798512T
Other languages
English (en)
Inventor
Kenji Soejima
Noriko Mimura
Hiroaki Maeda
Chikateru Nozaki
Takayoshi Hamamoto
Tomohiro Nakagaki
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE460479T1 publication Critical patent/ATE460479T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
AT03798512T 2002-09-25 2003-09-25 Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon ATE460479T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002279924 2002-09-25
JP2002377569 2002-12-26
PCT/JP2003/012280 WO2004029242A1 (ja) 2002-09-25 2003-09-25 フォンビルブランド因子特異的切断酵素に対する抗体及びそれを用いたアッセイ系

Publications (1)

Publication Number Publication Date
ATE460479T1 true ATE460479T1 (de) 2010-03-15

Family

ID=32044615

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03798512T ATE460479T1 (de) 2002-09-25 2003-09-25 Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon

Country Status (10)

Country Link
US (1) US7575872B2 (de)
EP (2) EP1544293B1 (de)
JP (3) JPWO2004029242A1 (de)
KR (1) KR101154550B1 (de)
CN (1) CN1701117B (de)
AT (1) ATE460479T1 (de)
AU (2) AU2003266632A1 (de)
CA (1) CA2499926C (de)
DE (1) DE60331666D1 (de)
WO (1) WO2004029242A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
WO2004083250A1 (ja) * 2003-03-17 2004-09-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物
US20040185042A1 (en) * 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
US8088624B2 (en) 2003-12-22 2012-01-03 Mitsubishi Kagaku Iatron, Inc. Method of detecting thrombosis by measuring von Willenbrand factor-cleaving protease
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
EP1816211A4 (de) * 2004-11-08 2008-11-12 Mitsubishi Kagaku Iatron Inc Verfahren zum nachweis von blutplättchenthrombose oder organversagen
JP5067917B2 (ja) * 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
AU2007210643B2 (en) * 2006-01-31 2013-09-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for determination of condition of disseminated intravascular coagulation syndrome
ES2386574T3 (es) 2006-02-16 2012-08-23 Mitsubishi Chemical Medience Corporation Procedimiento de detección de afección en paciente con alteración de la consciencia
JP2008136453A (ja) * 2006-12-05 2008-06-19 Mitsubishi Kagaku Iatron Inc フォンビレブランド因子切断酵素の活性阻害因子把握方法
WO2009001743A1 (ja) 2007-06-22 2008-12-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 新規adamts-13改変体
EP3388529A1 (de) * 2008-12-05 2018-10-17 Baxalta GmbH Verfahren zum messen der adamts13-vermittelten in-vivo-spaltung von von-willebrand-faktor und verwendungen davon
JP2013040912A (ja) * 2011-08-18 2013-02-28 Miyazakiken Sangyo Shien Zaidan 成人ｔ細胞白血病診断器具
US11597778B2 (en) 2015-04-07 2023-03-07 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to ADAMTS13 and uses thereof
EP3401685B1 (de) 2016-01-08 2021-12-01 Kyoto University Diagnoseverfahren und medikament mit adamts13 als hauptbestandteil
CN106008715B (zh) * 2016-07-18 2019-11-08 苏州大学附属第一医院 一种抗人血管性血友病因子裂解酶的抑制性单克隆抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049106A1 (en) * 2000-04-27 2001-12-06 Leonard Buckbinder ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
DE10034154A1 (de) * 2000-07-07 2002-01-24 Inst Polymerforschung Dresden Multifunktionelle Kopplungsagenzien mit zyklischen Iminoester- und Iminoethergruppen, Verfahren zu deren Herstellung und Verwendung
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2002279924A (ja) 2001-03-19 2002-09-27 Seiko Instruments Inc 大きな試料の観察・加工を可能とする集束イオンビーム装置
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof

Also Published As

Publication number Publication date
US20060251655A1 (en) 2006-11-09
CA2499926C (en) 2013-06-04
DE60331666D1 (de) 2010-04-22
JPWO2004029242A1 (ja) 2006-01-26
KR20050048647A (ko) 2005-05-24
EP1544293B1 (de) 2010-03-10
CN1701117A (zh) 2005-11-23
JP2009236925A (ja) 2009-10-15
EP1544293A1 (de) 2005-06-22
JP2013078319A (ja) 2013-05-02
EP2157178A1 (de) 2010-02-24
CA2499926A1 (en) 2004-04-08
AU2008202992A1 (en) 2008-07-31
EP1544293A4 (de) 2006-03-15
US7575872B2 (en) 2009-08-18
AU2003266632A1 (en) 2004-04-19
AU2008202992B2 (en) 2012-03-29
KR101154550B1 (ko) 2012-06-08
CN1701117B (zh) 2011-04-20
WO2004029242A1 (ja) 2004-04-08

Similar Documents

Publication Publication Date Title
ATE460479T1 (de) Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon
DE50306067D1 (de) Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
ATE159982T1 (de) Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
NO2010021I1 (no) Denosumab
BR9809443A (pt) Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão.
BRPI0416211A (pt) il-23 e seu receptor; reagentes relacionados e métodos
DK1625163T3 (da) Fremgangsmåde til at påvise proBNP med en monoklonal antistofbinding til aminosyrerne 38-43
DE240975T1 (de) Menschliches gamma-interferon-spezifisches rezeptorprotein, antikoerper gegen dieses protein, verfahren zur herstellung dieses proteins und dieses antikoerpers und dieses protein und diesen antikoerper enthaltende zusammensetzungen.
CN105378099A (zh) Hcv核心脂质结合结构域单克隆抗体
CN109596839A (zh) 人和肽素快速定量检测方法与试剂盒
CN1618017A (zh) 用于病人的样本中生物化学标记物的早期和同步检测的免疫测定法和试剂盒
Andrade et al. Immunosensors: Remaining problems in the development of remote, continuous, multi-channel devices
CN1639572A (zh) 用于抗－ingap抗体的测定
Hnasko The biochemical properties of antibodies and their fragments
US20230360747A1 (en) Improvements in or relating to quantitative analysis of samples
CN107474130A (zh) 一种阿莫西林人工抗原的合成方法
DE69031726D1 (de) Antikörper, ihre Herstellung und Verwendung
DE602006018694D1 (de) Rekombinante Expression von Rubella E1 Hüllenproteinvarianten als Chaperon-Fusionsproteine und seine Verwendung zum Nachweis von anti-Rubella Antikörper
DE502004008729D1 (de) Gegen das Prothrombin-Fragment F1+2 gerichtete Antikörper, ihre Herstellung und Verwendung
JP4153068B2 (ja) 蛍光免疫測定方法
DE60007195D1 (de) Antikörper und Diagnostizierverfahren zur Pestivirusdiagnose
WO2018100053A1 (en) Novel antibody for determination of adamts-13 activity
CN1252473C (zh) 肝细胞生长因子激活剂的抑制剂－1的抗体和其用途
JP4780405B2 (ja) 結合親和性を利用する被検物質の測定方法、及び被検物質の測定のための結合親和性解析の制御方法
ATE140233T1 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1544293

Country of ref document: EP